Friberger Ida, Nilsson Joachim N, Lu Li, Siikanen Jonathan, Ardenfors Oscar, Milton Stefan, Samén Erik, Goos Jeroen A C M, Carlsten Mattias, Holmin Staffan, Tran Thuy A
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
EJNMMI Res. 2023 Aug 8;13(1):73. doi: 10.1186/s13550-023-01021-1.
In vivo monitoring of cell biodistribution using positron emission tomography (PET) provides a quantitative non-invasive method to further optimize cell therapies and related new developments in the field. Our group has earlier optimized and evaluated the in vitro properties of two radiotracers,[Zr]Zr-(oxinate) and [Zr]Zr-DFO-NCS, for the radiolabelling of different cell types. Here, we performed a microPET study to assess the in vivo biodistribution of cells in rats using these two radiotracers. Human decidual stromal cells (hDSC) and rat macrophages (rMac) were radiolabelled with [Zr]Zr-(oxinate) or [Zr]Zr-DFO-NCS. Rats were intravenously injected with radiolabelled cells, and the in vivo biodistribution was monitored with microPET/CT imaging for up to day 7. Organ uptake was evaluated and presented as a percentage of injected activity per gram tissue (%IA/g) and total absorbed organ doses (mSv/MBq).
The biodistribution in vivo showed an immediate uptake in the lungs. Thereafter, [Zr]Zr-(oxinate) labelled cells migrated to the liver, while the signal from [Zr]Zr-DFO-NCS labelled cells lingered in the lungs. The differences in the in vivo behaviour for the same cell type appeared related to the radiotracer labelling. After 24 h, [Zr]Zr-(oxinate) labelled cells had over 70% higher liver uptake for both hDSC and rMac compared to [Zr]Zr-DFO-NCS labelled cells, whereas [Zr]Zr-DFO-NCS labelled cells showed over 60% higher uptake in the lungs compared to [Zr]Zr-(oxinate) labelled cells. This difference in both lung and liver uptake continued until day 7. Dosimetry calculations showed a higher effective dose (mSv/MBq) for [Zr]Zr-DFO-NCS compared to [Zr]Zr-(oxinate), for both cell types. Although the bone uptake was higher for [Zr]Zr-(oxinate) labelled cells, the prolonged uptake in the lungs contributed to a significant crossfire to bone marrow resulting in a higher bone dose.
The [Zr]Zr-DFO-NCS labelled cells suggest a prolonged accumulation in the lungs, while [Zr]Zr-(oxinate) suggests quicker clearance of the lungs followed by accumulation in the liver. Accumulation of radiolabelled cells in the liver corresponds to other cell-tracking methods. Further studies are required to determine the actual location of the [Zr]Zr-DFO-NCS labelled cell.
使用正电子发射断层扫描(PET)对细胞生物分布进行体内监测,提供了一种定量的非侵入性方法,可进一步优化细胞疗法及该领域的相关新进展。我们团队 earlier 优化并评估了两种放射性示踪剂[Zr]Zr-(肟酸盐)和[Zr]Zr-DFO-NCS的体外特性,用于不同细胞类型的放射性标记。在此,我们进行了一项微型PET研究,以评估使用这两种放射性示踪剂时大鼠体内细胞的生物分布。人蜕膜基质细胞(hDSC)和大鼠巨噬细胞(rMac)用[Zr]Zr-(肟酸盐)或[Zr]Zr-DFO-NCS进行放射性标记。给大鼠静脉注射放射性标记的细胞,并通过微型PET/CT成像监测体内生物分布长达7天。评估器官摄取情况,并以每克组织注射活性的百分比(%IA/g)和器官总吸收剂量(mSv/MBq)表示。
体内生物分布显示肺部立即摄取。此后,[Zr]Zr-(肟酸盐)标记的细胞迁移至肝脏,而[Zr]Zr-DFO-NCS标记的细胞的信号则在肺部持续存在。同一细胞类型在体内行为的差异似乎与放射性示踪剂标记有关。24小时后,与[Zr]Zr-DFO-NCS标记的细胞相比,[Zr]Zr-(肟酸盐)标记的hDSC和rMac细胞的肝脏摄取高出70%以上,而[Zr]Zr-DFO-NCS标记的细胞与[Zr]Zr-(肟酸盐)标记的细胞相比,肺部摄取高出60%以上。肺部和肝脏摄取的这种差异一直持续到第7天。剂量学计算表明,对于两种细胞类型,[Zr]Zr-DFO-NCS的有效剂量(mSv/MBq)高于[Zr]Zr-(肟酸盐)。尽管[Zr]Zr-(肟酸盐)标记的细胞的骨摄取较高,但肺部的长时间摄取导致对骨髓的显著交叉辐射,从而使骨剂量更高。
[Zr]Zr-DFO-NCS标记的细胞表明在肺部有长时间的积累,而[Zr]Zr-(肟酸盐)表明肺部清除更快,随后在肝脏中积累。放射性标记细胞在肝脏中的积累与其他细胞追踪方法一致。需要进一步研究以确定[Zr]Zr-DFO-NCS标记细胞的实际位置。